Key result
In vivo pretreatment with the endothelin receptor antagonist SB 209670 almost entirely blocked pronounced coronary vasoconstriction ex vivo in perfused hearts from polyarthritic rats.
Why the study?
Does in vivo pretreatment with the endothelin receptor antagonist SB 209670 prevent coronary vasoconstriction in perfused hearts from polyarthritic rats?
Population
Polyarthritic rats (perfused hearts ex vivo)
Design
Preclinical
Authors
Loading...
Endothelin antagonism may reduce coronary vasoconstriction in inflammatory arthritis models; leaves open translation to human disease.
Does in vivo pretreatment with the endothelin receptor antagonist SB 209670 prevent coronary vasoconstriction in perfused hearts from polyarthritic rats?
Endothelin receptor antagonism with SB 209670 prevents coronary vasoconstriction in a rat model of polyarthritis, suggesting a role for the endothelin system in inflammation-associated vascular dysfunction.
Warner et al. (1995) studied Polyarthritis. SB 209670 was evaluated on Coronary vasoconstriction. In vivo pretreatment with the endothelin receptor antagonist SB 209670 almost entirely blocked pronounced coronary vasoconstriction ex vivo in perfused hearts from polyarthritic rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: